EDGAR·FLOW

AEON Biopharma, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 5/100
What the filing says
Robert Bancroft (CEO) and John Bencich (CFO) certified on November 16, 2026 that AEON's Q3 2026 10-Q fairly presents financial condition and results, with effective disclosure controls and internal controls over financial reporting. No material weaknesses, significant deficiencies, or fraud disclosed. This is routine executive certification required by Sarbanes-Oxley.
Why this rating

Boilerplate SOX 302/906 certification exhibits; purely procedural and standard for all public companies. No substantive business information.

View original filing on SEC.gov ↗ AEON · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.